Sue Dil­lon, Karyn O'Neil steer fledg­ling Aro Bio­ther­a­peu­tics to $13M de­but — with J&J's bless­ing

When news first broke that R&D heavy­weights Sue Dil­lon and Karyn O’Neil left J&J to launch Aro Bio­ther­a­peu­tics, pre­cious lit­tle was known about the com­pa­ny …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.